Doxorubicin + Trabectedin + Dexamethasone
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Soft Tissue Sarcoma
Conditions
Soft Tissue Sarcoma, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms
Trial Timeline
Apr 1, 2005 → Oct 1, 2007
NCT ID
NCT00102609About Doxorubicin + Trabectedin + Dexamethasone
Doxorubicin + Trabectedin + Dexamethasone is a phase 1 stage product being developed by Johnson & Johnson for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00102609. Target conditions include Soft Tissue Sarcoma, Sarcoma, Neoplasms, Connective and Soft Tissue.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00102609 | Phase 1 | Completed |
Competing Products
20 competing products in Soft Tissue Sarcoma